Gujarat Kidney and Super Speciality IPO: GMP, Price, Important dates and more...
- Gabriela Galeena
- Dec 23, 2025
- 2 min read
The company has set a price band of ₹108 to ₹114 per equity share, with a lot size of 128 shares, translating to a minimum investment of ₹14,598 for retail investors.
IPO Snapshots
Detail | Value |
Total Issue Size | ₹250.80 Cr |
Fresh Issue | ₹250.80 Cr |
Offer for Sale | - |
Face Value | ₹2 |
Price Band | ₹108 to ₹114 |
Lot Size | 128 |
Minimum Investment | ₹14,592 |
Listing | BSE, NSE |
Opens | 22 December 2025 |
Closes | 24 December 2025 |
Gujarat Kidney & Super Speciality Limited, incorporated in 2019, is a Gujarat-based multispeciality healthcare provider offering secondary and tertiary care services. The company operates seven hospitals and four pharmacies across multiple cities in Gujarat. Its hospitals provide a wide range of services including general and advanced surgeries, orthopaedics, cardiology (non-interventional), obstetrics and gynaecology, diabetology, and critical care.
Financial Performance
Period Ended | Revenue from Operations (₹ Cr) | Profit After Tax (₹ Cr) |
FY 2025 | 40.40 | 9.50 |
FY 2024 | 5.48 | 1.71 |
FY 2023 | 0.00 | -0.01 |
GMP (Grey Market Premium)
Currently, the Grey Market Premium (GMP) of Gujarat Kidney IPO is ₹3.5, hinting at a potential listing price of ₹117.5 (cap price + latest GMP). This implies an expected gain/ loss of 3.07% per share at listing.
Peer Comparison
Company | CMP (₹) | Market Cap (₹ Cr) | P/E | Sales (₹ Cr) | OPM % | NP 12 M |
Gujarat Kidney and Super Speciality | - | 898.81 | - | 40.24 | 41.15 | 9.50 |
Yatharth Hospital & Trauma Care Services Limited | 690.80 | 6,656.21 | 43.70 | 988.13 | 24.39 | 152.51 |
GPT Healthcare Limited | 138 | 1,133 | 26.1 | 430 | 19.1 | 43.4 |
KMC Speciality Hospitals (India) Ltd | 77.9 | 1,271 | 41.8 | 264 | 26.1 | 30.4 |
Use of Proceeds
The company plans to deploy the IPO funds primarily toward expansion, acquisitions, capacity enhancement, and balance sheet strengthening, indicating a growth-oriented strategy.
Disclaimer: This content is for educational purposes only; please conduct your own research and consult a qualified investment advisor before making investment decisions.
Want to read more?
Subscribe to finsightsbysquareleague.com to keep reading this exclusive post.
